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The purpose of this research was to investigate the in vitro and in vivo anti-angiogenic 
properties of ceramide isolated from oyster (Crassostrea virginica). Ceramide was isolated from 
oyster by silicic acid chromatography, purified by alkaline hydrolysis, and analyzed by 
electrospray ionization mass spectrometry (ESI-MS). In vitro, the activity of ceramide on human 
hormone-dependent (MCF-7) and hormone-independent (MDA-MB-435s) breast cancer cells 
was evaluated for cell viability and proliferation, VEGF-induced cell migration and invasion, 
apoptosis, and autophagy. The activity of ceramide was also evaluated for VEGF-induced human 
umbilical vein endothelial cells (HUVEC) tube formation. The protein levels of vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF) in MCF-7 and MDA-MB435s 
breast cancer cells treated with ceramide were examined by ELISA. Autophagy was observed by 
the presence of autophagic vacuoles, and monodansylcadaverine was used as a marker for the 
detection of autolysosomes. The levels of the transcription factor NF-kB and the activity of 
phosphatidylinositol kinase were determined by ELISA and Western blot respectively from the 
cellular extracts of control and ceramide treated breast cancer cells. The activity of ceramide, in 
vivo, was evaluated for inhibition of bFGF-induced angiogenesis with a matrigel plug assay.  
The yield of ceramide methyl aminoethylphosphonate from deshelled oysters was 0.16% 
on a dry weight basis. The molecular size of isolated ceramide was 413 daltons. The viability of 
MCF-7 and MDA-MB-435s cells exposed to 125µM of ceramide for 48 h was reduced to 76% 
and 85%, respectively. The viability of MCF-7 and MDA-MB-435s cells exposed to 250 µM of 
ceramide for 48 h was reduced to and 38% and 45%, respectively. Ceramide at 50 µM inhibited 
tube formation by HUVEC in the presence of VEGF at 10ng/ml. Ceramide at 125 µM inhibited 
VEGF-induced MDA-MB-435s cell migration and invasion and also decreased VEGF, EGF 
 x
levels, and NF-kB activity in the conditioned media. Ceramide from oyster mediated MCF-7 and 
MDA-MB-435s breast cancer cell death by autophagy, respectively. In vivo, ceramide at 
30mg/kg body weight caused a 57% reduction in hemoglobin levels in the matrigel plug assay 
within seven days. Ceramide from oyster inhibited angiogenesis in vitro and in vivo. 





Sporadic breast cancer accounts for more than 95% of all breast cancer cases regardless 
of ethnic groups suggesting that primary prevention should be the ultimate goal for breast cancer 
control. Women who are carriers of BRCA1 or BRCA2 gene mutations have about 90% lifetime 
risk of developing breast cancer and represent 5% of all cases of breast cancer. The inability to 
predict the majority of breast cancer cases suggests that the prevention would be imporant as part 
of a broad program to reduce the incidence of breast cancer. It is thought lifelong dietary habits 
have a large influence on cancer development thus dietary changes may prevent breast cancer 
development (Hanf and Gonder, 2005; Tsubara et al., 2005; Kotsopoulos and Narod, 2005).  
Resistance to chemotherapy is often the result of defects in the apoptotic cell death 
cascade and a major reason for failure of cancer treatment. Bioactive compounds that can 
prevent the progression of breast cancer or overcome resistance while inducing breast cancer cell 
death would improve patient outcomes and prolong patient survival.  
Ceramides are sphingolipid-derived bioactive second messengers. These bioactive 
compounds are being actively studied as potential chemopreventive or chemotherapeutics 
because they are intimately involved in the regulation of cancer cell growth, differentiation, 
senescence, and cell death (Ogretmen and Hannun, 2004). Evidence shows that primary and 
metastatic cancer cells contain less endogenous ceramides compared to normal mucosa from the 
same patient indicating that ceramide biosynthesis process may be disrupted in cancer cells 
(Struckhoff et al., 2004). It has also been shown that radiation-resistant and multidrug resistant 
tumor cells do not generate or accumulate ceramides suggesting an alteration in sphingolipid 
pathway (Cai et al., 1997). As a proof of concept, treating cancer cells in vitro with exogenous 
ceramides almost always produce cell cycle arrest, senescence, differentiation, apoptosis or 
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autophagy (Radin, 2003; Scarlatti et al., 2004; Ogretmen and Hannun, 2004). Systemic delivery 
of exogenous C6-ceramide to syngeneic Balb/c mice models of breast adenocarcinoma 
significantly limited tumor growth (Stover et al., 2005). Putative mechanisms responsible for 
ceramide-induced apoptosis of mammary cancer cells include the accumulation of ceramides 
within the mitochondria leading to mitochondrial dysfunction, cytochrome c release and caspase 
activation, dephosphorylation of ceramide-activated protein phosphatase, control of calcium 
levels, and activation of cathepsin D and protein kinase C (Struckhoff et al., 2004; Bourbon et 
al., 2002; Radin, 2003; Chalfant et al., 2004; Ogretmen and Hannun, 2004; Stover et al., 2005). 
These data suggest that addition of exogenous ceramides to tumor cells represents an important 
mechanism for decreasing both tumor cell survival and makes ceramide an attractive bioactive 
compound for cancer prevention and/or treatment. 
While search for naturally occurring bioactive ceramides that may inhibit the progression 
of breast cancer, we have identified ceramide methyl aminoethylphosphonate in oyster 
(Matsubara et al, 1975) as an inhibitor of breast cancer cell growth and proliferation. The 
objectives of this study were to: 
1) Isolate and purify ceramide from oysters. 
2) Determine the anti angiogenic activity of ceramide in vitro using human umbilical vein 
endothelial cells and hormone-dependent and independent breast cancer cells, and  




2.1. Sphingolipids  
2.1.1. Introduction 
Sphingolipids belong to the family of membrane lipids that have important structural 
roles in controlling the fluidity and subdomain structure of the lipid bilayers (Futerman and 
Hannun, 2004). Sphingolipids represent the most chemically diverse class of biologically active 
lipids with a wide variety of biological activities. Eukaryotes and prokaryotes contain 
sphingolipids that are characterized by a common backbone sphingosine. The major 
sphingolipids in mammalian tissues include ceramides, sphingomyelins, cerebrosides, and 
gangliosides (Vesper et al., 1999). Sphingolipids are located in cellular membranes, lipoproteins 
and other lipid rich structures. They are very important for the maintenance of membrane 
structure and modulate the behavior of growth factor receptors and extracellular proteins. 
Sphingolipids act as bioeffector molecules, which are very important in various aspects of cancer 
biology such as cell growth, migration, survival, differentiation, senescence and apoptosis. As all 
these processes are very important in cancer development and progression, which ceramides 
having a great impact on anti-cancer therapy (Ogretmen and Hannun, 2004; Reynolds et al., 
2004; Modrak et al., 2006). The amino group of sphingosine base is substituted with a long chain 
fatty acid to produce ceramide, a major molecule in sphingolipid metabolism. Ceramide is the 
central molecule of the sphingolipid metabolism and is very important for cell regulation 
activities (Vesper et al., 1999; Ogretmen and Hannun, 2004). 
2.1.2. Importance of Sphingolipids to Nutrition 
Sphingolipids are constituents of most foods, but in very small amounts (Vesper et al., 
1999). There is no evidence for the importance of sphingolipids for growth. But sphingolipids 
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and their digestion products like ceramide and sphingosine are very important bioactive 
compounds that are important in cell regulation (Hakamori, 1991). Ceramides are taken up by 
the intestinal cells and degrades into sphingosine and fatty acids. Dietary sphingolipids do no 
contribute much to the calories of the body but they are essential nutrients against cancer and 
some other diseases. Due to their potent biological activities and occurrence in food, 
sphingolipids can be designated as functional components of food (Hannun and Obeid, 1995; 
Jaydev et al., 1995; Sweeney et al., 1998; Vesper et al., 1999). 
2.2. Ceramides 
2.2.1. Definition and Sources 
Ceramides belong to the family of sphingolipids composed of N-acylated sphingosine 
and a fatty acid. Ceramides are associated with wide variety of biological responses to 
extracellular stimuli, including proliferation, differentiation, growth arrest, cell cycle arrest, 
immune responses, senescence, and apoptosis (Hannun and Obeid, 2002; Kolesnick, 2002; 
Stover et al., 2003). 
In sphingolipid metabolism, the major modification takes place at the C1 hydroxyl group 
of ceramide (Fig 2.1). This hydroxyl group serves as acceptor for glucose and phosphorylcholine 
to form glycosphingolipid and sphingomyelin, respectively (Perry and Hannun, 1998). 
Ceramides are present in trace amounts in dairy products, vegetables, and marine 
animals. The amount of ceramide present varies from source to source and is generally less than 
0.1% (Ziesel et al., 1994; Whitaker, 1996; Vesper et al., 1999). The occurrence of ceramide 
aminoethylphosphonate and methylaminoethylphosphate in marine animals has been reported 
(Matsubara, 1975; Matsubara et al., 1990). Ceramide aminoethylphosphonate is a type of 
phosphonolipid that contains aminoethylphosphonic residue, with a phosphorus carbon bond 
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attached to lipid backbone sphingosine. Phosphonolipids belong to the class of sphingolipids and 
the first phosphonolipid identified was ceramide aminoethylphosphonate, which was found in 
sea anemone (Moschidis, 1985; Matsubara, 1990; Mukhamedova and Glushenkova, 2000). The 
structures of ceramide aminoethylphosphonate and ceramide methylaminophosphonate are given 
in fig 2.1a and 2.1b. 

















Figure 2.1b: Structure of Ceramide 2-methylaminoethylphosphonate 




























Figure 2.1c: Basic Structure of Ceramide 
n=number of carbon atoms 
 
The carbon atoms from 1-5 on sphingosine backbone are biologically important and 
consist of a primary and secondary hydroxyl group at C1 and C3. The amino group at  
C2 helps in the formation of amide bond to the fatty acid. The fatty acid portion is highly 
saturated in ceramide. There is a double bond located between C4 and C5, which is responsible 
for the induction of apoptosis (Perry and Hannun, 1998). And also the replacement of carbonyl 
group of the amide bond with a methylene group makes the molecule a potent inducer of 
apoptosis (Perry and Hannun, 1998; Pettus et al., 2002). 
2.2.3. Synthesis and Metabolism  
Ceramides, the basic structure of sphingolipids can be formed either by de novo synthesis 
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synthesis (Fig 2.3) starts on the surface of endoplasmic reticulum by condensation reaction 
between serine and palmitoyl Coenzyme A. The condensation reaction is the rate-limiting step, 
which is followed by reduction, acylation and desaturation. Condensation between serine and 
palmitoyl Coenzyme A forms ketosphinganine, catalyzed by the enzyme serine palmitoyl 
transferase. Ketosphinganine reduces the ketone group in presence of ketosphinganine reductase 
and forms sphinganine (Perry and Hannun, 1998).  
Sphinganine is acylated to dihydroceramide. This reaction is followed by the addition of 
double bond and converts acylated sphinganine to ceramide in presence of dihydroceramide 
saturase. Drugs such as vincristine, etoposide and paclitaxel and some ionizing agents generally 
stimulate the de novo synthesis of ceramide (Perry and Hannun, 1998; Pettus et al., 2002; 
Reynolds et al., 2004). 
Sphingomyelinases are very important enzymes in sphingolipid metabolism. These 
enzymes are activated by a wide variety of stress stimuli, resulting in increased ceramide levels. 
Sphingomyelinase translocates to outer cell membrane after activation by several surface 
receptors and hydrolyzes sphingomyelin to form ceramide (Segui et al., 2000; Kirschnek et al., 
2000; Grassme et al., 2002; Reynolds et al., 2004). 
Ceramides can accumulate in the cell or may be converted into a variety of metabolites. 
The anabolic and catabolic enzymes of ceramide can control ceramide metabolism (Fig 2.3). 
Phosphorylation of ceramide forms ceramide-1 phosphate and deacylation by ceramidase 
generates the sphingosine. Sphingosine can be further phosphorylated to sphingosine phosphate 
by sphingosine kinase. It can also be converted into sphingomyelin by sphingomyelin synthase 
by transferring the phosphoryl choline from phosphatidyl choline. Glycosylation of ceramide 
forms glucosylceramide (Mathias et al., 1998; Hannun et al., 2001; Reynolds et al., 2004). 
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Figure 2.3: Ceramides Metabolism (Perry and Hannun, 1998). 
2.3. Ceramides in Health and Disease 
2.3.1. Introduction 
Ceramide is central to sphingolipid metabolism and confers biological functions like anti 
proliferation, inhibition of migration, growth arrest, and cell death in cancer cells. Due to 
ceramides cell regulating effects on cancer cells, it has been called tumor suppressor lipid 
(Futerman and Hannun, 2004; Ogretman and Hannun, 2004; Ogretman, 2006). Ceramides play 
an important role in preventing diseases like cancer, diabetes and some neurodegenerative 
diseases. Ceramides have been shown to have wide range of biological effects ranging from cell 
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proliferation to cell death (Crawford et al., 2003). Endothelial cell proliferation and migration, 
inflammation, angiogenesis, metastasis are the hallmarks of degenerative disease such as 
diabetes, heart disease, age related macular degeneration, and cancer (Carameliet and Jain, 
2000). 
2.3.2. Ceramides under Physiological and Pathological Conditions 
Ceramides participate in cell regulating properties like cell death, differentiation, and cell 
cycle arrest (Hannun and Obeid, 2002; Kolesnick, 2002). Due to these properties ceramides have 
been extensively studied in the treatment of diseases like cancer, diabetes, heart disease, and 
other neurodegenerative diseases (Stover et al., 2005; Struckhoff et al., 2004). Ceramide 
metabolism is altered in tumor cells, and the enzymes targeting ceramide metabolism are 
expressed differently between cancer cells and normal cells (Crawford et al., 2003).  
Under normal physiological conditions angiogenesis is tightly regulated. Angiogenesis is 
altered in diseases like cancer and can lead to excessive cell proliferation and migration or 
insufficient blood vessel formation. In diseased conditions like cancer and diabetes, and some 
other diseases, angiogenesis is imbalanced and leads to production of new blood vessels. In 
others like infertility and diabetic wounds, angiogenesis is characterized by insufficient blood 
vessel formation (Carameliet and Jain, 2000). Ceramides mediate anti proliferative pathways, 
inhibits cell survival mechanisms by regulating signaling cascades controlled by protein 
phosphatases and also induces cell death by autophagy or apoptosis. Increasing ceramide 
production in cancer cells leads to increased cytotoxicity in cancer cells (Reynolds et al., 2004; 
Ogretmen and Hannun, 2004; Ogretmen, 2006). 
2.3.3. Ceramides and Cancer 
Cancer cells are structurally and functionally abnormal and have highly disorganized  
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vasculature with excessive branching. Ceramides plays an important role in cell death signaling 
by cytokines, chemotherapeutic agents, and radiation (Radin, 2001). Exposure of cancer cells to 
radiation therapy leads to apoptosis and a decrease in Bcl-2 proteins. Ceramides inhibit the 
antiproliferative pathways by regulating multiple signaling cascades controlled by phosphatases, 
kinases or cathepsin (Pettus et al., 2002; Simstein et al., 2003; Mochizuki et al., 2004; Scaralatti 
et al., 2004 ;Takai et al., 2005).  
Ceramides are generated in response to chemotherapeutics and radiation by de novo 
synthesis or by hydrolysis of sphingomyelin (Struckhoff et al., 2004; Modrak et al., 2006). 
Recent investigations have shown that the metabolism of ceramides has influence on the 
effectiveness of various cancer therapeutics (Senchenkov et al., 2001). Novel ceramide analogs 
have been used as potential chemotherapeutic agents in breast cancer cells (Stover and Kester, 
2003). Chemotherapeutic drugs such as vincristine, etoposide, paclitaxel, and doxorubicin are 
used to increase intracellular ceramide concentration (Struckhoff et al., 2004). Agents that affect 
the production or accumulation of ceramides can change the response to chemotherapy as 
ceramides mediate diverse biological process (Olshefski and Ladisch, 2001; Litvat et al., 2003; 
Struckhoff et al., 2004). An increase in the levels of ceramides in tumor cells represents an 
important mechanism for decreasing tumor survival (Struckhoff et al., 2004). 
2.3.3.1 Breast Cancer 
Breast cancer is the most common cancer of women. It is the second leading cause of 
death from cancer after lung cancer in women and occurs with 100-fold greater incidence in 
females than males (Chu et al., 1996; Tsubara et al., 2005; Williams et al., 2006). Breast cancer 
is a multistep disease characterized by the up regulation of multiple signal pathways that promote 
growth, proliferation, inhibit apoptosis, and evoke the formation of new blood vessels. It is a 
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heterogeneous disease that differs from woman to woman. Breast cancer cells escape normal 
growth control by molecular alterations involving tumor suppressor gene and oncogene products 
(Coradini and Daidone and 2004). Mutations in BRCA1 and BRCA2 disrupt the breast cell 
homeostasis and leads to cancer. Women who are carriers of BRCA1 and BRCA2 gene 
mutations have about 90% lifetime risk of developing breast cancer and represent 5% of all cases 
of breast cancer (Adem et al., 2004). There are several factors associated with breast cancer such 
as age, family history, late menopause, obesity, and alcohol and tobacco consumption. Breast 
cancer can be divided into two types: hormone dependent and hormone independent. Hormone 
dependent breast cancer cells express receptors to estrogen and progesterone hormones 
(Williams et al., 2006). 
Chemotherapy is the main approach to treat breast cancer cells. Chemotherapeutic 
compounds produce their cytotoxic effects by interfering with the function of DNA or RNA, or 
increase the concentration of some bioavailable compounds to act against cancer cells (Kitano, 
2004). Chemotherapeutic drugs cause damage to the adjacent cells. Chemoresistance is also 
accompanied by the progression of breast cancers from hormone dependent, non metastatic, anti 
estrogen-sensitive phenotype to a hormone independent, invasive, metastatic, antiestrogen-
resistant phenotype (Campbell et al., 2001; Simstein et al., 2003). Cancer cells often generate 
their own growth signals leading to metastasis, angiogenesis, and cellular immortality. (Kitano, 
2004). Tumors are highly self-sufficient in generating their own proliferative growth signals, 
invasion and metastasis, evasion of apoptosis, and leading to neo- angiogenesis (Hanahan and 
Weinberg, 2000). Tumor cells respond well to the drugs initially, but may become resistant over 
time. Addition of exogenous ceramide to tumor cells represents an important mechanism for cell 
death and limited cell growth and makes ceramide an attractive bioactive compound for cancer 
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treatment (Vesper et al., 1999; Samsel et al., 2004; Ogretmen and Hannun, 2004; Stover et al., 
2005; Struckhoff et al., 2005). 
2.3.4. Mode of Action of Ceramides on Breast Cancer Cells 
2.3.4.1. Inhibition of Angiogenesis 
2.3.4.1.1. Physiological and Pathological Angiogenesis 
Angiogenesis is the formation of new blood vessels from preexisting vessels. The 
formation of blood vessels is essential for organ growth and repair and important in both 
physiological and pathological conditions (Papetti and Herman, 2002).  
Vascular endothelial growth factor (VEGF) is the major stimulator in angiogenesis. 
VEGF stimulates the formation of blood vessels and their permeability. Some other factors 
thought to promote angiogenesis are fibroblast growth factor (FGF), angiopoietin (Ang-2), 
platelet-derived growth factor (PDGF), and tumor necrosis factor alpha (TNF-α) and hormones 
like estrogen, progesterone, and androgens. Metalloproteinase and membrane bound proteins 
also stimulate angiogenesis. Table 2.1 lists some of the stimulators and inhibitors of angiogenesis 
known to date. 
Table 2.1: List of Angiogenesis Stimulators and Inhibitors (Losso and Bansode, 2004) 
 Stimulators of  Angiogenesis Inhibitors of Angiogenesis 
Vascular endothelial growth factor (VEGF) Angiostatin 
Fibroblast growth factors: acidic (aFGF) and 
basic (bFGF) 
Interferon alpha/beta/gamma 
Platelet-derived endothelial cell growth factor 
(PD-ECGF) 
Transforming growth factor-beta 
Platelet-derived growth factor-BB (PDGF-BB) Human chrionic gonadotropin 
Tumor necrosis factor-alpha (TNF-alpha Heparinases 
 
Interleukin-8 (IL-8) Endostatin 
Angiogenin Metalloproteinase inhibitors 
Angiopoietin-1 Platelet factor 
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There are two types of angiogenesis: physiological and pathological angiogenesis. 
Physiological angiogenesis plays an important role in tissue development, reproduction, wound 
healing, oxygen delivery to muscles, and tissue repair. In physiological conditions there is a 
balance between stimulators and inhibitors of angiogenesis. Physiological angiogenesis is 
important for reproduction, for connective tissue formation, development of child in a mother’s 
womb, maintenance of vascular integrity during wound healing, repair of damaged tissue, 
oxygen delivery to working muscles, and bone growth and repair (Papetti and Herman, 2002). 
The mechanism of physiological angiogenesis includes the following steps: 
1) pericyte removal from endothelium and angiopoietin-2 (Ang-2)-catalyze transformation of 
endothelial cells from a stable to a proliferative phenotype; 2) growth factors, VEGF and VE 
cadherin catalyze vessel hyper-permeability and matrix remodeling by the action of serine and 
matrix metalloproteinase; 3) growth factor (VEGF, FGF, and EGF) catalyze endothelial cell 
proliferation; 4) integrin (αvβ3) and growth factors, VEGF, and FGF; catalyze endothelial cell 
migration 5) Vecadherin (Vecad) and ephrin B2/ephrin B4 catalyze cell-cell contact; 6) FGF, 
PDGF, TNF-α, and Eph-2A catalyze tube formation as blood conduits; 7) PDGF- and 
Ang1/Tie2-catalyze proliferation and migration of mesenchymal cells along the new vessels and 
TGF-β catalyze pericyte differentiation into mature pericytes; and finally 8) Ang1/Tie2, PDGF, 
VE cadherins and TGF-β catalyzed vessel stabilization (Papetti and Herman and 2002; Losso 
and Bansode, 2004). 
Pathological angiogenesis occurs when there is imbalance between angiogenesis 
inhibitors and stimulators. There are two types of pathological angiogenesis: excessive and 
insufficient angiogenesis. Excessive angiogenesis occurs when angiogenic stimulators out 
balance angiogenic inhibitors. Insufficient angiogenesis occurs when there is a deficiency of 
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stimulators. The mechanism of excessive angiogenesis involves: 1) retraction of pericytes from 
the abluminal surface of the capillary, 2) release of proteases from the activated endothelial cells, 
3) protease-catalyzed dissolution of the basement membrane surrounding the pre-existing 
vessels, 4) endothelial cell migration toward an angiogenic stimulus and their proliferation, 5) 
formation of tube-like structures, 6) fusion of the formed vessels, and 7) initiation of blood 


















Figure 2.4: Degenerative Diseases Associated with Pathological Angiogenesis (Losso, 2002) 
 
Insufficient angiogenesis is characterized by 1) insufficient vascularization, 2) delayed 
formation of granulation tissue, 3) decreased collagen content, 4) low breaking strength 
compared to normal tissue, loss of vascular tone, 5) higher content of oxidized lipids, 6) absence 
of microtubular structures, 7) impaired collateral vessel formation, and 8) impaired blood vessels 
(Papetti and Herman, 2002). 
Understanding angiogenesis and its characteristics in tumor growth has provided ways to 
block the process. Antiangiogenic compounds have been used in the treatment of cancer (Ferrara 
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and Kerbel, 2005). Angiogenesis requires tumor cells to release stimulators and proteolytic 
enzymes to degrade extracellular matrix for migration and proliferation. Depending on how they 
function, angiogenesis inhibitors can be divided into the following categories: 1) agents that 
inhibit the vascular endothelial cell activation; 2) agents that inhibit the vascular endothelial cell 
migration, proliferation, and survival; 3) compounds that inhibit the extracellular matrix 
degradation; and 4) compounds that inhibit integrin activation (Kerbel et al., 2001; Viloria-Petit 
et al., 2001). Depending on the target, angiogenesis inhibitors can be categorized into two types: 
direct and indirect inhibitors. Direct angiogenesis inhibitors prevent vascular endothelial cell 
proliferation and migration. Direct inhibitors either block or decrease growth factors, which are 
necessary for migration, proliferation, and cell death. Indirect angiogenesis inhibitors block the 
expression activity of growth factors or its receptor that activate angiogenesis in tumor. As these 
growth factors are the product of genes, indirect inhibitors not only control proliferation and 
migration but also disrupt the production of angiogenic factors (Albo et al., 2004, Kerbel and 
Ferrara, 2005). 
It has been hypothesized that antiangiogenesis would be an effective strategy to treat 
human cancer (Folkman, 1971; Folkman, 1995; Carameliet and Jain, 2000; Ferrara and Kerbel, 
2005). Ceramides are associated with several biological processes like cell proliferation, 
differentiation, growth arrest (Hannun and Obeid, 2002; Kolesnick, 2002; Struckhoff et al., 
2004). Ceramides such as C6 and C8 ceramides inhibited angiogenesis in breast cancer cells 
(Crawford et al., 2003; Struckhoff et al., 2004; Takai et al., 2005).  
2.3.4.1.2 Angiogenesis and Breast cancer 
Pathological angiogenesis a hallmark of cancer and various other diseases. Angiogenesis 
is essential for growth and progression of breast cancer cells (Toi et al., 2002). VEGF is the key 
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molecule in breast cancer cells which stimulates endothelial cell proliferation and migration 
within the tumor (Toi et al., 1995; Toi et al., 2002). 
Biomarkers associated with the highest impact on breast cancer development and 
progression include c-myc, HER-1/EGFR, HER-2/neu, estrogen receptor-ß, cyclin A, B, D, and 
E, p53, bcl-2, telomerase activity, hTERT/hTR, CD31/PECAM-1, VEGF, HIF-1α(Toi et al., 
2002). However, other biomarkers of breast cancer associated with the aggressiveness of the 
disease include matrix metalloproteinase -2 and -9, cathepsin D, NFk-B, Hsp90, COX-2, PI3K, 
AKT, MAPK, P-glycoproteins, Ki67, Wnt-1, and AP-1 (Coradini and Daidone, 2004). There are 
other markers, considered as indirect biomarkers such as heparanase and MMP-1 for which the 
correlation with breast cancer has not been clearly established. However, most cancer biomarkers 
have been identified in the invasive and proliferative stages of the disease are related to cell 
proliferation, invasion, migration, hormone-dependence, apoptosis, and metastasis (Jong et al., 
2002).  
2.3.4.1.3. Ceramides and Breast Cancer 
Ceramide analogs have been extensively used in treating breast cancer cells (Struckhoff 
et al., 2004). Treating breast cancer cells with chemotherapeutic agents such as vincristine, 
daunorubicin, and gemcitabine increases the intracellular concentration of ceramides by inducing 
the de novo pathway (Struckhoff et al., 2004). Exogenous ceramides can also be utilized to treat 
breast cancer cells. Ceramides can be delivered to the cancer cells by using liposomal vehicles to 
target the breast cancer cells. It has been reported that liposomal delivery of ceramide analogs 
caused significantly greater accumulation of ceramide in breast cancer cells (Radin, 2001; Stover 
and Kester, 2003). The bioactive ceramides can be incorporated into conventional liposomal 
vehicles for improved drug delivery and release. Exogenous delivery of ceramides in liposomes 
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is more effective and has shown inhibitory effects on breast cancer cells (Stover and Kester, 
2003). Delivery of ceramides to breast cancer cells caused in vitro cell death and in vivo delivery 
of ceramide slowed tumor growth in breast cancer cells (Stover et al., 2003; Futerman and 
Hannun, 2004; Ogretman, 2006). Novel ceramide analogs showed cytotoxic effects in drug 
resistant breast cancer cells (Crawford et al., 2003). Naturally occurring ceramide found in 
oysters may have similar biological activity against cancer cells but this hypothesis has never 
been investigated. 
2.3.4.2. Cell Death Mechanisms 
Cell death in cancer cells is caused by the activation of various enzymes that are 
stimulated by some bioactive compounds. Ceramide is a bioactive compound that plays an 
important role in cell death in cancer cells by autophagy and or apoptosis (Hannun and Obeid, 
1995; Mochizuki et al., 2002). In general there are three different types of cellular death that 
occurs in cells to maintain cellular homeostasis: autophagy, apoptosis, and necrosis. Ceramides 
cause cell death in cancer cells by autophagy or apoptosis. 
2.3.4.2.1. Autophagy 
Autophagy is a degradative pathway, which involves the removal of cytoplasmic portions 
and intracellular organelles in a vacuole called autophagosome. It is also called as programmed 
cell death II (PCD II). These vacuoles fuse with lysosome and organelles are degraded and 
resulting macromolecules recycled. It can be initiated by conditions like starvation, stress, and 
hormone treatment (Van Sluijters et al., 2000). There are three types of autophagy: 
macroautophagy, microautophagy, and chaperone mediated autophagy. 
Macroautophagy also called autophagy plays an important role in diseases like cancer, 
muscular disorders, and neurodegenerative diseases (Shintani and Kilonsky, 2004). Autophagy is 
 19
a complex process that occurs in several steps. This PCD II is initiated by the formation of an 
autophagosome. Cytoplasm and various cell organelles such as endoplasmic reticulum, 
mitochondria and peroxisomes are sequestered by a membrane to form an autophagosome. A 
smooth membrane from a ribosome free region of the endoplasmic reticulum covers the 
autophagosome. Thereafter the autophagosome fuses with the lysosome and finally degrades the 
cell (Munafo and Colombo, 2001). Autophagy protects against cancer cells by removing the 
damaged cells, increasing protein degradation, and promoting autophagic cell death (Levine and 
Yuan, 2005). The main characteristic feature of autophagy is its dependence on tumor suppressor 
genes acting in the formation of the autophagosome and in signaling pathways regulating 
autophagy. Beclin-I is one of the tumor suppressor genes that plays an important role with class 
III phosphatidylinositol-3-kinase complex in the autophagic process. Beclin-I inhibits cellular 
proliferation in the autophagic process. Up regulation of Beclin-I and inhibition of 
phosphatidylinositol-3-kinase are very important in autophagic cell death in cancer cells (Lavieu 
et al., 2006). Ceramides have been used to inhibit the phosphotidylinositol-3-kinase and 
stimulate the beclin-I against breast cancer cells (Scarlatti et al., 2004; Lavieu et al., 2006). 
Beclin-I expression is reduced in invasive breast cancers. Many drugs have been reported to 
trigger cell death by autophagy in cancer cells by increasing levels of ceramide (Scaralatti et al., 
2004). 
2.3.4.2.2. Apoptosis 
Apoptosis is one of the main types of cellular death and also called programmed cell 
death І (PCD I). Apoptosis is an active process that depends on the network of a sequence of 
signaling events that lead to cell death. Apoptosis is a discrete sequence of morphological 
changes causing cell death with DNA cleavage by chromatin segregation with nuclear 
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membrane. It maintains cellular homeostasis in organisms, which is very important in the aspect 
of disease development in humans (Simstein et al., 2003; Hetz et al., 2005). 
Programmed cell death I is characterized by the following steps: a) cells become circular 
due to the action of caspases that have been activated inside the cell. b) chromatin degrades and 
condenses into small compact patches c) the nuclear envelope becomes discontinuous and the 
DNA inside it is fragmented and the cell breaks into apoptotic bodies, which are then 
phagocytosed. During apoptosis, membranes are well maintained and do not affect the behavior 
of other cells and the resulting fragments (apoptotic bodies) are phagocytosed by surrounding 
cells (Simstein et al., 2003). 
The key molecules that control PCD are members of the death associated protein kinase 
(DAPK) family. Death associated protein kinase –І (DAPk) mainly activates apoptosis through a 
caspase dependent pathway (Shintani and Kilonsky, 2004). The molecular events of apoptosis can 
be divided into three steps: 1) apoptosis initiation by inducing agent, 2) caspase activation by a 
signal transduction cascade, and 3) cellular degradation by proteolytic cleavage.  There are several 
genes, which are controlled by extracellular factors that are involved in apoptosis. Caspases are a 
group of proteases, the initiators in apoptotic pathway, which contain a cysteine active site with 
aspartate substrate specificity. Activation of caspases involves both extrinsic and intrinsic 
pathways. Intrinsic pathway involves Bcl-2 proteins and the release of cytochrome C from 
mitochondria. Cytochrome C activates the adaptor protein, followed by the activation of 
procaspase-9, which causes the activation of effector caspases. Extrinsic pathway is induced by 
death receptor protein complexes that cleave procaspase-8 (Simstein et al., 2003; Reynolds et al., 
2004). Caspase-8 cleavage and activation initiates the caspase cascade. After the induction of 
caspase 8, the extrinsic and intrinsic pathways unite at the level of effector caspases. These 
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effector caspases cleave cellular signaling molecules; cleave DNA repair enzymes, cellular, and 
nuclear proteins (Simstein et al., 2003). Additional markers of apoptosis include DNA 
fragmentation, phosphatidylserine exposure at the cells surface, and the characterization of key 
molecules, such as cysteine proteases of the caspase family and members of Bcl-2 family of 
proteins (Danial and Korsmeyer, 2004; Hetz et al., 2005). 
It has been reported ceramides mediate cell proliferation, differentiation, cell cycle arrest, 
and apoptosis (Reynolds et al., 2004). Ceramides are secondary messenger of apoptosis manifested 
by significant increase in ceramide levels before the onset of apoptosis and activation of caspases. 
Ceramides play an important role in the execution of apoptosis (Pettus et al., 2002; Simstein et al., 
2003; Reynolds et al., 2004; Modrak et al., 2006). Ceramides activate the key molecules like 
protein kinase, and mitochondria for the induction of apoptosis. Chemotherapeutic drugs have been 
used to induce the synthesis of ceramide, cause the activation of protein kinase and down regulate 
the antiapoptotic signals leading to apoptosis (Stover and Kester, 2003). 
2.3.4.2.3. Necrosis 
Necrosis also called ‘accidental cell death’ is characterized by rapid swelling of the dying 
cell, rupture of the plasma membrane, and release of cytoplasmic content into the cell 
environment. Although necrotic cell death has great impact in pathological conditions such as 
heart diseases and several neurodegenerative diseases, the molecular mechanism of necrotic cell 
death is poorly understood. Necrosis occurs under conditions of cellular injury and is related to the 
loss of homeostasis and drastic decreases in ATP levels (Hetz et al., 2005). In recent years it has 
been reported that necrotic cell death occurs under normal physiological conditions. Additional 
evidence shows that traditional apoptotic pathways lead to necrotic cell death under certain 
conditions (Hetz et al., 2002, Leyton and Quest, 2004). Nonapoptotic cell death plays an important 
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role in the control of cell viability under normal physiological conditions, when injury or other 
disease triggers cell death. The understandings of molecular approaches to cell death are important 
as these different forms of cell death share some common features at the morphological level. 
Understanding of the cell death mechanisms will help in the development of more efficient 
therapies for the treatment of human diseases like cancer, autoimmune, and neurological diseases 





































MATERIALS AND METHODS 
 
3.1. Isolation and Purification of Ceramide from Oyster 
3.1.1. Introduction 
Ceramide aminoethylphosphonate (CAEPn) and ceramide methylaminophosphonate 
(CMAEPn) have been isolated from the abductor, gills, and viscera of the oysters (Matsubara, 
1975). Studies have shown that CAEPn and CMAEPn are widely distributed in a variety of 
fresh-water and marine bivalves, and edible mollusks (Kariotoglou and Mastronicolis,2003), 
snails (Hori et al, 1996; 1967), gastropods (Komai et al, 1973) sea anemones (Karlsson and 
Samuelsson, 1974; Adosraku et al., 1996), and sea stars (Mukhamedova and Glushenkova, 
2000). 
3.1.2. Materials  
Oyster samples were purchased from P & J New Orleans, LA. Silica gel (32-63 mesh 
size) was purchased from Bodman Industries, Aston, PA. The Column for chromatography was 
purchased from Bio Rad Laboratories, Hercules, CA. Organic solvents used were of analytical 
grade. 
3.1.3. Isolation and Purification of CMAEPn 
Ceramide methylaminoethylphosphonate was extracted using a modification of the 
method of Matsubara et al. (1975). Oysters were blended and lyophilized. The lyophilized 
samples were extracted with acetone (1:1 w/v) with shaking for 1 h at 4°C and the mixture was 
left at 4°C for two days. Acetone extract removed neutral lipids and water from the oyster 
samples. The residue was extracted five times with acetone. The remaining residue, which was 
free of neutral lipids, was extracted with chloroform: methanol (2:1 v/v) twice. Extracts were 
dried and applied to a silicic acid column. Crude ceramide was eluted with chloroform: methanol 
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(9:1 v/v) from the silicic acid column. Crude ceramide was purified further by alkaline 
hydrolysis to remove glycerophospholipids and again passed through silicic acid column. The 
column was eluted with a series of chloroform: methanol (98:2 v/v) to remove fatty acid methyl 
esters and then acetone: methanol (9:1 v/v) to obtain ceramide methylaminoethylphosphonate. 
3.1.4. Identification of Ceramide by Electrospray Ionization (ESI)-Mass spectrometry (MS) 
The isolated ceramide methylaminoethylphosphonate was analyzed by ESI-MS. The 
samples were dissolved in methanol: water with 1% acetic acid. ESI-MS of ceramide 
methylaminoethylphosphonate was recorded in the positive-ion mode using a PE Sciex Qstar 
(Quadrupole-TOF hybrid, Applied Biosystems, Foster City, CA). The spectrum was recorded at 
an accelerating voltage of 4500 V. 
3.2. In Vitro Anti- angiogenic Activity of Ceramide 
3.2.1. Introduction 
Angiogenesis is the formation of new blood vessels from the existing vasculature. The 
principal cells involved are endothelial cells. First, endothelial cells escape from their location by 
breaking through the basement membrane to form new blood vessels. Then endothelial cells 
migrate toward a stimulus that might be released by tumor cells or wound associated 
macrophages. The migrated endothelial cells then proliferate and organize into three-dimensional 
tubular structures ultimately forming new blood vessels. Each of these steps, basement 
membrane disruption, cell migration, cell proliferation, and tube formation can be tested in vitro 
(Auerbach et al., 2003; Staton et al., 2004).In vitro assays of angiogenesis are tested 
predominantly on migration, proliferation, and tube formation in response to exogenous 
inhibitory compounds. Cell proliferation assays are easy to perform and reproducible, imparting 
themselves to accurate quantification (Auerbach et al., 2000; Auerbach et al., 2003). Generally 
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there are two classes of proliferation assays: some of which determine cell number and the other 
measure cell cycle kinetics. Cell numbers can be counted using a haemocytometer or by 
electronic counter. Another method to measure the cell proliferation is by using tetrazolium salt, 
which is cleaved by active mitochondria to form a dark blue product. The product is measured 
colorimetrically as a measure of proliferation as living cells produce the formazan blue product 
(Denizot and Lang, 1986; Wemme et al., 1992; Staton et al., 2004).Cell migration and invasion 
are also very important for embryonic development and functioning of adult organisms (Valster 
et al., 2005). There are several tests that can be used to determine the migration response of 
endothelial cells to angiogenesis stimulating or inhibiting factors. Endothelial cells move by a 
process called chemotaxis, along a gradient of angiogenesis-stimulating factors such as VEGF. A 
modified Boyden chamber assay has been used to assess the migration of endothelial cells. In 
this assay, endothelial cells are placed on top of a filter and migrate across the filter in response 
to an angiogenic factor placed in the lower chamber. The major advantage of this assay is the 
high sensitivity to small differences in concentration (Auerbach et al., 2003; Staton et al., 2004). 
A tube formation assay is the most specific test for angiogenesis. The tube formation assay 
measures the ability of endothelial cells to form three-dimensional structures. Endothelial cells 
form tubules spontaneously with the appropriate extracellular matrix components. The formation 
of tubes can be observed under a microscope. Tube formation can be improved by using collagen 
or fibrin clots on the culture discs (Auerbach et al., 2003). 
3.2.2. Materials  
Ceramide was dissolved in DMSO to obtain 20 mM stock, stored at –200C in aliquots, 
and diluted according to the required concentrations. CellTiter 96 AQueous One solution was 
obtained from Promega (Madison, WI). Chemicon in vitro Angiogenesis kit ECM 625 was used 
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for tube formation assay. Cell migration and cell invasion kits were purchased from Cell Biolabs 
(San Diego, CA). TransAM Nuclear Extract and TransAM-NFκB kits were purchased from 
Active Motif (Carlsbad, CA). BCA Protein assay kit was purchased from Pierce Biotechnology 
(Rockford, IL). Caspase–Glo 9 Assay was purchased from Promega (Madison, WI.). Human 
VEGF and EGF ELISA kits were purchased from Peprotech, Rock Hill, NJ. 
3.2.3. Cell Cultures and Harvesting 
Estrogen dependent MCF-7 and estrogen independent MDA-MB 435s cell lines were 
used. MCF-7 cell line is a BRCA1-competent hormone-sensitive and non-invasive luminal breast 
cancer cell line that expresses ER+ and p53. The MDA-MB 435 s breast cancer cells are spindle 
shaped and established from pleural effusion. MDA-MB 435 s cell line is estrogen independent 
and BRCA1 incompetent. MCF-7 and MDA-MB 435s breast cancer cell lines were obtained 
from American Type Culture Collection (Rockville, MD) and harvested according to ATCC 
procedure. The cells were grown as a monolayer and attained 100% confluence. 
3.2.4. Cell Proliferation and Viability Assay  
Confluent cultures of MCF-7 and MDA-MB435s breast cancer cells were seeded on 96-
well plates at a density of approximately 2x 104cells/well in a total volume of 100 µl. The cells 
were grown for 24 h prior to treatment. MCF-7 cells were treated by addition of 10 ng/ml of 17β-
estradiol. Ceramide was dissolved in dimethylsulfoxide to achieve final concentrations of 50-500 
µM while making sure that DMSO concentration did not exceed 1%. Untreated control cancer 
cells received less than 1% of dimethylsulfoxide. All experiments were carried out in triplicates. 
Replicates of culture plates were prepared and incubated for 24, 48, or 72 h in a humidified 
incubator containing 5% CO2 at 37 ºC. At the end of the incubation period, the CellTiter 96 
AQueous One solution (Promega, Madison, WI) was used as follows. Twenty micro liters of the 
 27
tetrazolium solution was added to each well and the plate was incubated in a humidified 5% CO2 
incubator at 370C for one hour. The plate was read at 490 nm using a Spectra Max Plus ELISA 
plate reader (Molecular Devices, Sunnyvale, CA). Each concentration of the inhibitor was done 
in triplicates. Cell viability and proliferation were normalized to the levels in untreated control 
cells to determine the percentage of viable cells.  
3.2.5. Cell Migration Assay 
The effect of ceramides on MDA-MB435s cell motility, an important pre-requisite for 
angiogenesis, was investigated by performing endothelial cell migration assay. The assay was 
carried in a 96-well disposable chamber (Cell Biolabs Inc, San Diego, CA) following the 
manufacturer’s instructions. MDA-MB 435s (1.0 x 106 cells) in 100 µl of media was added to the 
membrane. The wells of the feeder tray were loaded with 150 µl of media containing 10 ng/ml 
VEGF. The plate was incubated in a cell culture incubator at 5% CO2, 370C for 4 h. MDA-MB- 
435s cells were treated with concentrations of 50-125 µM ceramide or DMSO (vehicle). At the 
end of incubation period, the cells were dislodged from the underside of the membrane, using 
cell detachment buffer and lysed with lysis buffer along with the dye and 150 µl of the mixture 
was transferred to a 96-well plate suitable for fluorescence measurement. The plate was read at 
480nm/520 nm using Perkin Elmer LS 50B spectro fluorimeter. 
3.2.6. Cell Invasion Assay 
Endothelial cell invasiveness was assayed using the fluorometric format CytoSelectTM 
96-well Cell Invasion Assay (Cell Biolabs Inc, San Diego, CA) following the manufacturer’s 
instructions. MDA-MB 435s (2.0 x 106 cells) in 100 µl was added to the membrane. The wells of 
the feeder tray were loaded with 150 µl of media containing 10 ng/ml of VEGF. The plate was 
incubated in a cell culture incubator at 5% CO2, 37°C for 4 h. Cells were treated with ceramide at  
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concentrations of 50-125 µM and controls were treated with 0.1% DMSO (vehicle). At the end 
of incubation period, the cells were dislodged from the underside of the membrane, using cell 
detachment buffer and lysed with lysis buffer along with the dye and 150 µl of the mixture was 
transferred to a 96-well plate suitable for fluorescence measurement. The plate was read at 
480nm/520 nm using Perkin Elmer LS 50B fluorometer. 
3.2.7. Tube Formation Assay 
 For the tube formation assay human umbilical vein endothelial cells (HUVEC) were 
used. After preparing the gel matrix, as per the manufacturer’s instructions, and allowing it to 
solidification. HUVEC cells (1.0 x 104 cells in 100 µl) were seeded onto the surface of the 
polymerized ECmatrix (Chemicon, Temecula, CA), alone or mixed with 50 µM of ceramide 
dissolved in DMSO in the presence of 10 ng/ml of VEGF. The plate was incubated at 37°C for 6 
h. Tube formation was inspected and photographed using a Leitz phase contrast inverted 
microscope 
3.2.8. Quantification of Apoptosis 
Detection of apoptosis was performed using the Caspase Assay (Promega, Madison, WI). 
Briefly, MCF-7 cells and MDA-MB-435s cells were treated with125 µM 250 µM of ceramide, 
respectively and incubated for 48 h. At the end of the incubation period, the cells were treated 
with 100 µl of Caspase- Glo 9 reagent incubated for 1 h and the luminescence of the solution was 
measured using a Perkin Elmer LS 50B luminometer. 
3.2.9. Quantification and Visualization of Autophagic Vacuoles 
MCF-7 cells were treated with 125 µM of ceramide and MDA-MB 435s cells were 
treated with 250 µM of ceramide for 48 h. For visualization of autophagic vacuoles cells were 
grown on cover slips for 48 h and labeled with 0.05 mM monodansylcadaverine (MDC) in PBS 
 29
at 37°C for 10 minutes. After incubation cells were washed four times with PBS and analyzed by 
fluorescence microscopy. For quantification of autophagic vacuoles cells, were plated in 96-well 
plates and treated with ceramide followed by incubation with 0.05 mM MDC in PBS at 37°C for 
10 minutes. After incubation, cells were washed with PBS four times and collected in 10 mM 
Tris-HCl, pH 8 containing 0.1% Triton X-100. Intracellular MDC was measured at 380/520 nm 
using Perkin Elmer LS 50B spectro fluorometer. DNA fluorescence was measured by adding 
ethidium bromide to a final concentration of 0.2 µM and measured at 530/590 nm using Perkin 
Elmer LS 50B spectro fluorometer (Munafo and Colombo, 2004). 
3.2.10. Protein Extraction, Immuno Precipitation, and Western Blotting 
MCF-7 and MDA-MB 435s cells were plated on 6-well dishes and treated with the 125 
µM and 250 µM of ceramide, respectively for 48 h. After the treatment, supernatant was 
collected for the quantification of growth factors VEGF and EGF. The cells were washed with 
ice cold PBS. Cytoplasmic and nuclear fractions were obtained using Nuclear Extraction kit 
(Active Motif, Carlsbad, CA). The protein concentrations for supernatant, cytoplasm, and 
nuclear fraction were obtained using BCA protein assay kit (Pierce, Rockford, IL).  
Cytoplasmic proteins were immunoprecipitated using immunoprecipitation/western blot 
protocol (Santa Cruz Biotechnology, CA). For immunoprecipitation, 300 µg of cell extract was 
incubated with anti-PI3K at 4°C on an end-to end rotator. The supernatant was centrifuged at 
10,000x g for 10 min, and protein A/G beads were added. The mixture was rotated for 3 h at 4°C 
and the immunocomplexes were washed with lysis buffer three times. SDS sample buffer was 
added to the beads, and the beads were incubated at 95°C for 5 min and the supernatant subjected 
to western blot analysis. Electrophoretic separation was performed using 4-12% Bis-Tris gels 
(Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membrane. Membranes were 
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blocked with 5% nonfat dry milk in PBS/Tween 20 (0.05%), followed by incubation with an anti 
PI3K antibody (1:1000 in 10% milk/PBS-T). Visualization of the bound primary antibody was 
done by probing with horseradish peroxidase-conjugated secondary antibodies (1:1000), and 
exposure to chromogenic detection reagent. 
3.2.11. ELISA 
3.2.11.1. Quantification of VEGF  
VEGF levels in the conditioned medium were determined by ELISA using the VEGF 
ELISA protocol from Peprotech (Rock Hill, NJ) following the manufacturer’s instructions. 
Samples of control MCF-7 and MDA-MB435s breast cancer cells and ceramide treated samples 
were analyzed. The amount of VEGF was detected using the VEGF standard curve, established 
with purified VEGF in the range of 0-4000 pg/ml. 
3.2.11.2. Quantification of EGF 
EGF in the conditioned media was quantified by using Human EGF ELISA kit 
(Peprotech, Rocky Hill, NJ). In this assay purified rabbit anti human EGF antibodies were used 
to determine the levels of EGF in ceramide treated cells and control. The amount of EGF was 
calculated using a standard curve established with purified EGF in the range of 0-4000pg/ml. 
3.2.11.3. Quantification of Nuclear Factor-kappa B (NF-κB) 
NF-κB levels in the nuclear extract of controls and ceramide treated breast cancer cells 
were determined using the NF- κB ELISA kit (Active Motif Carlsbad, CA). 
3.3. In Vivo Anti-angiogenic Activity of Ceramide 
3.3.1. Introduction 
Angiogenesis, the formation of new blood vessels is very important for tumor growth. 
Hence the inhibition of tumor angiogenesis has become an important approach in cancer research 
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(Folkman, 1995; Carmeliet and Jain, 2000; Kragh et al., 2004). One of the important challenges 
in angiogenesis studies is the selection of the appropriate assay. It has been reported that a 
compound affecting cell proliferation and migration may not necessarily regulates endothelial 
cell activity in vivo (Staton et al., 2004; Liekens et al., 2001). So the evaluation of in vivo 
angiogenesis is very important to assess anti-angiogenic activity as a prerequisite for the 
discovery and characterization of anti angiogenic compounds (Staton et al., 2004; Kragh et al., 
2003; Ribatti and Vacca, 1999; Jain et al., 1997).  
There are many assays developed for in vivo angiogenesis. Examples include the matrigel 
plug assay, chick chorioallantoic membrane (CAM) assay, the window models, rabbit corneal 
assay, and the disc angiogenesis system ( Auerbach et al., 2003; Kragh et al., 2003 ;Kragh et al., 
2004 ). The optimal in vivo angiogenesis assay should be able to promote the induction of 
significant and reproducible amount of new blood vessels, the induced vessels should easily be 
quantified by more than one method. The matrigel plug assay originally utilized for rabbits. 
However, due to costs it has been shifted to small animals such as rodents like rat and mouse 
(Kragh et al., 2003; Kragh et al., 2004). In this assay, angiogenesis inducing compounds such as 
basic fibroblast growth factor (bFGF) are introduced into the matrigel and injected 
subcutaneously into the animals. The matrigel is liquid at 0° C and solidifies at room temperature 
and above. After injection, the matrigel solidifies and allows penetration by host cells that causes 
vascularization. After 7 days angiogenesis is assessed by determining the hemoglobin 
concentration in the matrigel or by histological examination of newly formed blood vessels 
(Kragh et al., 2003; Akhtar et al., 2002). 
Matrigel plug assay was used to assess the antiangiogenic activity of ceramide in vivo. 
Rats were used in the assay. 
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3.3.2. Materials and Methods 
3.3.2.1. Animals 
Female six-week old Sprague-Dawley rats were purchased from an in-house breeding 
colony and housed in the Vivarium of the School of Veterinary Medicine at Louisiana State 
University. The facility is operated by the Division of Laboratory Animal Medicine and is 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, 
International. The Louisiana State University Institutional Animal Care and Use Committee 
approved the study. 
Animals were serologically determined to be free of the following organisms: Sendai 
virus, sialodacryoadenitis virus, Kilham’s rat virus, H-1 virus, rat parvovirus, pneumonia virus of 
mice, transmissible murine encephalomyelitis virus, adenovirus, lymphocytic choriomeningitis 
virus, and Mycoplasma pulmonis.  No endo or ectoparasites were found, nor were any respiratory 
or enteric bacterial pathogens cultured. Rats were housed in polycarbonate microisolator cages 
on corn cob bedding, (7097, Harlan Teklad, Madison, WI) with a 12:12 light cycle. Room 
temperature was maintained between 68 and 72°F, and humidity between 40 and 60%. Feed (Lab 
Diet® 5001, PMI® International, Inc., Brentwood, MO) and water (via water bottles) were 
provided ad libitum. Rats were out bred, they are not closely related. 
3.3.2.2 Preparation of Matrigel for Injection 
BD Matrigel Matrix (BD Biosciences, Franklin Lakes, NJ) is a soluble basement 
membrane extract of the Engelbreth-Holm-Swarm (EHS) tumor that gels at room temperature to 
form a genuine reconstituted basement membrane. The major components of BD Matrigel 
Matrix are laminin, collagen IV, entactin and heparin sulfate proteoglycan, growth factors, 
collagenases, and plasminogen activators. Matrigel solidifies at room temperature. Basic 
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fibroblast growth factor (BD Biosciences) was used at 300 ng per ml of matrigel. Two different 
types of matrigel were prepared for control and treatment (ceramide). Control matrigel was 
prepared with basic fibroblast growth factor without ceramide. Treatment matrigel included both 
bFGF and ceramide. Ceramide was dissolved in DMSO and mixed in matrigel at of thirty mg of 
ceramide was used per kilogram weight of the rat.  
3.3.2.3. Subcutaneous Injection of Matrigel into the Rats 
Prior to injection rats were anesthetized with isoflurane. The isoflurane was delivered at 
2-3% via nose cone and 100% oxygen used as the carrier gas. After the animals were 
anesthetized, the flank was shaved and disinfected with ethyl alcohol. Matrigel premixed with 
basic fibroblast growth factor, with or without ceramide, was injected subcutaneously to both 
sides of flank. A total of 1 ml of matrigel with 300 ng of bFGF per each rat was used in control 
and ceramide for the treatment. Ceramide was used as 30 mg per kg body wt of rat. Control 
matrigel was injected on the left flank while the right flank contained the treatment matrigel. The 
same sequence was maintained for all 5 rats. Sterilized syringes and needles were used to inject 
the matrigel subcutaneously. Matrigel was gel at 4°C and solidified as soon as it was injected 
into the rat. After the injection the rats were kept in their standard animal housing with free 
access to food and water. Figure 3.1 depicts a rat injected with matrigel plugs in both left and 
right flank. 
3.3.2.4. Quantification of Angiogenesis 
Matrigel was removed from the rats after 7 days. Rats were euthanized through inhalation 
of CO2 and the matrigel plugs were carefully removed from the underneath the skin. Matrigel 
plugs were gently washed with saline (0.9% NaCl), homogenized with 2 ml of distilled water on 
ice and centrifuged at 10,000 rpm for 6 min at 4°C to get clear solution. The supernatant was 
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used in duplicates to measure the hemoglobin concentration along with standards using Drabkins 
reagent at 540 nm in an ELISA plate reader. Hemoglobin standards were prepared and measured 
simultaneously at 540 nm. Hemoglobin was expressed in mg of hemoglobin per ml of plug. 
 
Figure 3.1: Matrigel Plugs on the Flank of Rat 
3.4. Statistical Analysis 
Statistical analysis was performed by paired t-test, one-way analysis of variance 

























RESULTS AND DISCUSSION 
4.1 Ceramide Identification by Electrospray Ionization (ESI) –Mass Spectrometry (MS) 
The yield of ceramide methylaminoethylphophonate was 0.16 %. Molecular species of 
ceramide was identified using electrospray ionization mass spectrometry (ESI-MS). The ESI-MS 
spectra gave one strong protonated molecular ion [M+H] (+) at m/z 413 with two other 
molecular ions at m/z 803 and 429 (Figure 4.1). Collision induced dissociation on ceramide 
produced product ions at m/z 55.01, 104.98, 203.05, 219.02. Alkaline hydrolysis of ceramide 
showed that the presence of a fragment at 55 and 97 and indicated the presence of phosphonate 
and phosphate groups, respectively. In the positive mode, the ions at m/z 140 and 138 originated 




Figure 4.1: Ceramide Identification by ESI-MS  
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4.2. In-Vitro Angiogenesis Assays 
 
4.2.1. CMAEPn Inhibits Cell Proliferation and Viability in Breast Cancer Cells 
 
Breast cancer cells were incubated with 0-500 µM of ceramide for 0-48 h. Cell 
proliferation and viability determined by cell morphology under the microscope showed that 
cells died dose-dependently within 24 h. At concentration above 125 µM, both MCF-7 and 
MDA-MB 435s showed less number of viable cells after 24 h than untreated MCF-7 and MDA-
MB 435s cells. At concentrations below 125 µM more viable cells were observed (Figure 4.2-
4.5). 
                   
 
                    
 
Proliferation was significantly inhibited at 125 and 250 µM of ceramide treated MCF-7 
and MDA-MB-435s cells, respectively. Viability was reduced to 76% and 38% with the 
treatment of 125 and 250 µM of ceramide respectively in MCF-7 cells (Fig 4.6). At 500 µM the 
number of viable cells was very low. In MDA-MB-435s cells the viability was reduced to 85% 
and 45% at 125 and 250 µM of ceramide for 48 h treatment. Viability was reduced to 27% at 500 
µM ceramide concentration (Fig 4.7). 
Figure 4.2: MCF-7 Control Figure 4.3: MCF-7 Treated with 100 µM  
Ceramide                   
Figure 4.4: MDA-MB-435s Control 
Figure 4.5: MDA-MB-435s Treated 




























Figure 4.6: Viability and Proliferation of Control and Ceramide Treated MCF-7 Breast Cancer 
Cells 


























Figure 4.7: Viability and Proliferation of Control and Ceramide Treated MDA-MB-435s Breast 
Cancer Cells 
* Indicates the significant difference at P<0.05 compared to control 
  * 
   * 
      * 
      * 
* 
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Ceramides inhibit the cell proliferation and viability by the hydrolysis of ceramide to 
sphingosine-1- phosphate or by the formation of glucosylceramide (Radin, 2003).  
The ceramide aminoethylphosphonate from oysters was effective in inhibiting the 
proliferation and viability of both breast cancer cell lines (MCF-7 and MDA-MB 435s). Cell 
proliferation is the important step in angiogenesis 
4.2.2. CMAEPn Decreases the Levels of VEGF in Treated Breast Cancer Cells 
         The VEGF levels in the CMAEPn treated MCF-7 and MDA-MB-435s cells were lower 
than the controls (Fig 4.8-4.9). The concentration of ceramide used for the determination of 
VEGF levels ranged from 50-200 µM. The VEGF levels in the controls of MCF-7 and MDA-
MB-435s cells were 246 and 291 pg/ml, respectively. The levels of VEGF in 200 µM ceramide 
treated MCF-7 and MDA-MB-435s were 115 and 145 pg/ml in MCF-7 and MDA-MB-435s 
breast cancer cells. The levels of VEGF were reduced significantly at 200 µM in both MCF-7 




















Figure 4.8: VEGF Levels in Control and Ceramide Treated MCF-7 Cells 
























Figure 4.9: VEGF Levels in Control and Ceramide Treated MDA-MB-435s Cells  
* Indicates the significant difference at P<0.05 compared to control 
 
There was 49% and 46% reduction of VEGF levels in MCF-7 and MDA-MB-435s cells 
treated with 200 µM ceramide. VEGF is a very important angiogenic stimulator in migration and 
proliferation of endothelial cells. Cell proliferation and migration are very important processes in 
angiogenesis. CMAEPn from oyster reduced the levels of VEGF in both MCF-7 and MDA-MB- 
435s breast cancer cells 
4.2.3 CMAEPn Inhibits the Levels of EGF in MCF-7 and MDA-MB-435s Cells 
 
MCF-7 and MDA-MB-435s breast cancer cells were treated with 50-200 µM of ceramide 
concentration and incubated for 48 h. EGF levels were determined using EGF ELISA protocol. 
The range of EGF in MCF-7 and MDA-MB-435 breast cancer cells was determined as 106-165 
pg/ml and 123-189 pg/ml, respectively (Fig 4.10-4.11).Controls MCF-7 and MDA-MB-435s 
contained to be 194 and 228 pg/ml EGF respectively. The concentration of EGF in 200 µM 
ceramide treated MCF-7 and MDA-MB-435s were 106 and 123 pg/ml, respectively.  
* 



















Figure 4.10: EGF Levels in Control and Ceramide Treated MCF-7 Cells 



















Figure 4.11: EGF levels in Control and Ceramide Treated MDA-MB-435s cells 
* Indicates the significant difference at P<0.05 compared to control 
  * 
   * 
**
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The levels of EGF in MCF-7 and MDA-MB-435s breast cancer cells were reduced by 
65% and 64% respectively. EGF is also an important stimulator of angiogenic processes. The 
results of this study show that CMAEPn is an inhibitor of EGF in MCF-7 and MDA-MB-435S 
breast cancer cells and may regulates the process of angiogenesis in breast cancer cells 
4.2.4. CMAEPn Inhibits Breast Cancer Cell Migration  
Invasive breast cancer cells MDA-MB 435s were used for the migration studies. Breast 
cancer cells were treated with CMAEPn from 0-125 µmole/l for 48 h followed by evaluation of 
cell migration in the presence of VEGF as chemoattractant. There was a significant inhibition of 















Figure 4.12: Cell Migration of Control and Ceramide Treated Breast Cancer Cells  
* Indicates the significant difference at P<0.05 compared to control 
 
Endothelial cells migrate by a process called chemotaxis, caused by angiogenesis-
inducing growth factor such as VEGF.  Inhibition of VEGF receptors reduces the migration of 
endothelial cells. Reduced migration of ceramide treated cell in presence of VEGF may be 




ceramide treated cells were analyzed (4.2.2.) and the significant difference between the control 
and ceramide treated cells may explain the reduced migration of breast cancer cells. 
4.2.5. CMAEPn Inhibits Breast Cancer Cell Invasion  
MDA-MB-435s invasive breast cancer cell line was used for invasion studies and cells 













Figure 4.13: Cell Invasion of Control and Ceramide Treated Breast Cancer Cells  
* Indicates the significant difference at P<0.05 compared to control 
At 125 µM concentration cell invasion was significantly inhibited than at 62.5µM 
ceramide and control. The difference between the invasion of untreated cells and ceramide 
treated cells shows that ceramide was effective in inhibiting the invasion of breast cancer cells. 
Invasion of endothelial cells depend on the stability of extracellular matrix (ECM) and the 
stability of ECM can be imbalanced by proteases. CMAEPn from oyster may inhibit the action 
of proteases and stabilizes ECM, which assists in the reduction of breast cancer cell invasion. 
4.2.6. CMAEPn Inhibits Endothelial Cell Tube Formation  
On a synthetic basement membrane matrix, cells are capable of morphological 




organized three-dimensional cords. The alignment of endothelial cells in capillary-like structures 
is a functional trait that is crucial to angiogenesis.  
In the presence of 10 ng/ml of VEGF, human umbilical vein endothelial cells (HUVEC 
plated on the EC matrix aligned and formed capillary-like structures within 6h (Figure 4.14). 
CMAEPn inhibited tube formation within 6h. At 50 µM ceramide, the capillary-like network of 
the ECmatrix was completely disrupted (Figure 4.15). 
                        
 
 4.2.7. Ceramide Methylaminoethylphosphonate Mediated Cell Death 
Both hormone dependent and independent breast cancer cells, MCF-7 and MDA-MB 
435s were studied for the detection of apoptosis after treatment with ceramide. 125 and 250 µM 
of ceramide concentrations were used for MCF-7 and MDA-MB-435s cells, respectively. The 
concentration at which the cells died was to explain the cell death. As apoptosis is directly 
associated with the stimulation of caspase activity, caspase- activity was assessed following 
treatment of MCF-7 and MDA-MB-435s with CMAEPn. Cells that were treated with the CAEPn 
showed significant decrease in the activity of caspases (Fig 4.16-4.17). Untreated cells had 
higher levels of caspases activity for both cell lines (Fig 4.16-4.17). Caspase activity decreased 
in ceramide treated MCF-7 and MDA-MB-435s cells and indicated ceramide caused caspase 
independent cell death.  
Figure 4.14: HUVEC Control Figure 4.15: HUVEC Control 






















Figure 4.16: Caspase Activity of Control and Ceramide (125 µM) treated MCF-7 Cells 





















Figure 4.17 Caspase Activity of Control and Ceramide (250 µM) Treated MDA-MB-435s Cells 




The accumulation of intracellular ceramide by induction, modification of endogenous 
ceramide metabolism, or exogenous supply of synthetic ceramides causes cancer cells to die by 
apoptosis may be a useful approach to cancer treatment (Lucci et al., 1999; Shabbits and Mayer, 
2003; Wang et al., 2003; Chan et al., 2006).Ceramide is the key regulator of apoptosis and 
activates the apoptotic proteins such as caspases, ceramide activated protein kinase (CAPK), 
cathepsin D, and serine/threonine protein phosphatases (Pettus et al., 2002). Elevated levels of 
cathepsin D was observed in MCF-7 cells treated with C6 ceramide (Bansode, 2005).It has been 
shown that some synthetic ceramides mediate caspase independent cell death in cancer cells 
(Mochizuki et al., 2002; Scaralatti et al., 2004; Thon et al., 2005). CMAEPn from oyster also 
showed decreased activity of caspases in MCF-7 and MDA-MB-435s, indicating that ceramide 
from oyster may not be effective in causing cell death by apoptosis. 
4.2.8. Ceramide Methylaminoethylphosphonate Mediated Autophagy 
Breast cancer cells were grown on cover slips, treated with CMAEPn and incubated for 
48 h. The concentration of ceramide used for MCF-7 and MDA-MB-435s cells were 125 and 
250 µM, respectively. Cell death was observed within 48 h. The cells were treated with 
monodansylcadaverine (MDC) and washed PBS, and observed under a fluorescent microscope 
for autophagic vacuoles. Both MCF-7 and MDA-MB-435s cells showed autophagic vacuoles 









































Figure 4.22: MDC Incorporation into Control and Ceramide Treated MCF-7 Cells  
* Indicates the significant difference at P<0.05 
 
Intracellular MDC was measured for both MCF-7 and MDA-MB-435 cells. More MDC 
was incorporated in ceramide treated cells than the control cells (Fig 4.22-4.23). 
MDC is a specific marker for autolysosomes (Biederbick et al., 1995). MDC 
incorporation was assessed for the visualization of autolysosomes. Ceramide treated cells 
showed an increased number of autophagic vacuoles than control in both breast cancer cell lines 
MCF-7 and MDA-MB-435s, respectively. There were no autophagic vacuoles observed in both 
controls, indicating that ceramide caused cell death by autophagy (Munafo and Colombo, 2001). 
   * 
Figure 4.20: MDA-MB-435s Control Figure 4.21: Ceramide Treated MDA-MB-435s 
Cells 
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It has been shown that ceramides induces cell death by non apoptotic pathway, 
autophagy. Ceramides are involved in regulation of autophagy by non-mutually exclusive two 
mechanisms. Ceramides inhibit class III PI3K signaling pathways and stimulates beclin I protein 
and mediates autophagy (Scaralatti et al., 2004). The protein kinases involved in the autophagic 





















Figure 4.23: MDC Incorporation into Control and Ceramide Treated MDA-MB 435s Breast 
Cancer Cells. 
* Indicates the significant difference at P<0.05 
Ceramides stimulate autophagy by interfering with class I PI3K signaling pathways and 
increases the expression of autophagic genes. More over ceramide levels are lower in cancer 
cells than normal cells, suggesting that ceramide is considered to be an important factor in the 
regulation of autophagy (Selzner et al., 2001).The presence of PI3K was confirmed by western 
blot. MCF-7 & MDA-MB-435s controls showed the presence of PI3K (Fig 4.24). CMAEPn 
* 
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treated MCF-7& MDA-MB-435s cells contained undetected levels of PI3K as shown by the 
absence of bands in ceramide treated cells. 
  
 
Figure 4.24: Western blot Analysis of PI3K in Control and Ceramide Treated MCF-7 and MDA-
MB-435s Cells 
 
1- MCF-7 Control, 2- MDA-MB-435s Control, 3-MCF-7 treated with 125 µM ceramide, and  
4-MDA-MB-435s treated with 250 µM ceramide. 
 
4.2.9 CMAEPn Inhibits Nuclear Factor-kappa B (NF-κB) Activation 
 
NF-κB inactivation is important for cancer cell death as it promotes cell proliferation and 
survival (Fulda et al., 1998; Toker, 1998). CMAEPn treatment inactivated NF-κB activity in 
























Figure 4.25: NF-κB (p65) Activity in Control and Ceramide Treated MCF-7 and MDA-MB-435s 
Cells 
* Indicates the significant difference at P<0.05 
*
*


























Figure 4.26: NF-κB (p50) Activity in Control and Ceramide Treated MCF-7 and MDA-MB-435s 
Cells 
* Indicates the significant difference at P<0.05 
 
NF-κB is a multisubunit nuclear transcription factor that regulates cellular functions such 
as cell growth, cell development, and adaptive responses to redox balance. In its inactive form, 
NF-κB resides in the cytoplasm and binds to the inhibitory proteins that shield the DNA binding 
site. It is over expressed in breast cancer cell lines and stimulates cell survival and proliferation.  
So the inactivation of NF-κB leads to cell death by autophagy or apoptosis (Simstein et al., 
2003). CMAEPn from oyster inactivated the NF-κB subunits p50 and p65 in both MCF-7 and 
MDA-MB-435s breast cancer cells. 
4.3. In Vivo Angiogenesis Assay 
4.3.1. CMAEPn Inhibition of In Vivo Angiogenesis 
After 7 days, the subcutaneously injected matrigel plugs containing bFGF with or without 
ceramide were quantitatively analyzed by optical density reading at 540 nm. Growth factor bFGF 





before injection) whereas CMAEPn inhibited bFGF induced angiogenesis (Fig 4.27 and Fig 4.28 
respectively). 
The plugs were homogenized and centrifuged to obtain a clear solution. Optical density at 
540 nm was taken to measure the hemoglobin concentration. Control plugs had higher 
hemoglobin concentration and ceramide treated matrigel plugs had lower levels (Fig 4.29). The 
average hemoglobin concentration was higher in the control matrigel (37.91mg/ml) than that 
seen in the treatment matrigel (21.623mg/ml).Treatment of ceramide varied from rat to rat, but 
the results was consistent except for rat #1. All the other four rats showed increased angiogenesis 
in control plugs and inhibition of angiogenesis in ceramide treated Matrigel plugs 
                     
 
Regardless of the in vitro tests, in vivo tests are necessary for accurate evaluation of 
angiogenesis (Auerbach et al, 2003). There is no standard in vivo angiogenesis assay and the 
limitation to progress in angiogenesis has been the availability of reproducible, simple, and 
quantitative assay (Kragh et al, 2003). We used a simple quantitative in vivo angiogenesis assay, 
Matrigel plug assay, in our study. Matrigel is easy to handle and subcutaneous injection of 
  
Figure 4.28: Ceramide Treated Matrigel plug Figure 4.27: Control Matrigel Plug 
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matrigel and growth factor exposure to the animal are same. In the present study, we tested the 
anti angiogenic activity of the ceramide. Ceramide was added to matrigel premixed with growth 
bFGF and subcutaneously injected to the rat. After 7 days matrigel plugs were removed from the 
rat skin. The control showed more blood vessels by visual observation indicating that bFGF 
induced angiogenesis and ceramide treated matrigel plugs showed less blood vessels than control 
, indicating the anti angiogenic activity of ceramide. These results show that bFGF induced 
angiogenesis in matrigel as the matrigel plug was avascular prior to injection. We found that 

























Figure 4.29 Hemoglobin Concentration of Control and Treated Matrigel Plugs of the Rats 
The average hemoglobin concentration of controls was ±37.91 mg/ml and for ceramide 
treated was ± 21.623 mg/ml. There was 57% of inhibition of hemoglobin levels with the 
ceramide treatment within 7 days. The difference in hemoglobin concentration between controls 
and ceramide treated matrigel plugs demonstrate that ceramide inhibited bFGF induced 




SUMMARY AND CONCLUSION 
 
The main objective of this study was to isolate, purify ceramide aminoethylphosphonate 
from oyster and determine the anti angiogenic properties of the isolated ceramide using MCF-7 
and MDA-MB435s breast cancer cells. 
Ceramide methylaminoethylphosphonate (CMAEPn) was isolated from oysters by a 
series of organic solvent extractions and followed by silicic acid chromatography. CMAEPn was 
identified by ESI-MS. The yield of ceramide methylaminoethylphosphonate was 0.16% on dry 
weight basis. The purified CMAEPn was tested for its anti angiogenic properties by in vitro and 
in vivo angiogenesis assays. 
 From the in vitro angiogenesis assays it was found that, CMAEPn greatly inhibited 
viability and proliferation of MCF-7 and MDA-MB-435s breast cancer cells. The ceramide 
inhibited the migration and invasion of invasive MDA-MB-435s breast cancer cells. At 50 µM, 
ceramide inhibited the formation of tubules by endothelial cells In the presence of ceramide 
VEGF levels in MCF-7 and MDA-MB-435s were reduced by 49% and 46% respectively. The 
levels of EGF were reduced by 65 and 64% in MCF-7 and MDA-MB-435s respectively with the 
treatment of ceramide. CMAEPn also inactivated the NF-kB, which promotes cell survival and 
proliferation. Both MCF-7 and MDA-MB-435s breast cancer cells showed low caspase activity 
treated with the 125 and 250 µM of ceramide, respectively. Oyster CMAEPn caused cell death 
by autophagy in both MCF-7 and MDA-MB-435s breast cancer cells. Results of western blot 
indicated that CMAEPn inhibited the activity of phosphatidylinositol kinase in MCF-7 and 
MDA-MB-435s breast cancer cells. 
In vivo angiogenesis was assessed by matrigel plug assay. CMAEPn at 30mg/kg body wt 
inhibited the formation of blood vessels in vivo. Treated matrigel plugs had lower values of 
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hemoglobin than the controls suggesting a lower number of blood vessels. Hemoglobin levels 
were 57% lower with the ceramide treatment. 
Overall in vitro and in vivo assay results suggest that ceramide methyl amino 
ethylphosphonte was effective against hormone dependent MCF-7and hormone independent 
MDA-MB-435s breast cancer cells. The results of this study demonstrate that oyster ceramide 
inhibited angiogenesis in vitro and in vivo. Moreover, oyster ceramide inhibited the viability of 
hormone dependent and hormone independent breast cancer cell by inactivating VEGF, EGF, 
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